M&A Deal Summary

Qiagen N.V Acquires NeuMoDx Molecular

On September 17, 2020, Qiagen N.V acquired life science company NeuMoDx Molecular for 248M USD

Acquisition Highlights
  • This is Qiagen N.V’s 6th transaction in the Life Science sector.
  • This is Qiagen N.V’s largest (disclosed) transaction.
  • This is Qiagen N.V’s 10th transaction in the United States.
  • This is Qiagen N.V’s 1st transaction in Michigan.

M&A Deal Summary
Date 2020-09-17
Target NeuMoDx Molecular
Sector Life Science
Buyer(s) Qiagen N.V
Deal Type Add-on Acquisition
Deal Value 248M USD

Target

NeuMoDx Molecular

Ann Arbor, Michigan, United States
NeuMoDx Molecular, Inc. designs and develops revolutionary molecular diagnostic solutions for hospital and clinical reference laboratories. NeuMoDx Molecular was founded in 2012 and is based in Ann Arbor, Michigan.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Qiagen N.V

Venlo, Netherlands
Category Company
Founded 1984
Sector Life Science
Employees5,200
Revenue 1.5B USD (2019)
DESCRIPTION

QIAGEN N.V. is a Netherlands holding company publically traded on NASDAQ and Frankfurt Prime Standard. The Company is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular insights. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Qiagen was founded in 1986 and is based in Venlo, the Netherlands.

DEAL STATS #
Overall 14 of 16
Sector (Life Science) 6 of 7
Type (Add-on Acquisition) 13 of 15
State (Michigan) 1 of 1
Country (United States) 10 of 11
Year (2020) 1 of 1
Size (of disclosed) 1 of 10
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-01-08 NeXtal Biotechnologies

Holland, Ohio, United States

NeXtal Biotechnologies specializes in the production of unique screens and plates for protein crystallization, an important step in the complex process of structural biology studies and structure-based drug design. NeXtal Biotechnologies is based in Holland, Ohio.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-05-11 BLIRT

Gdańsk, Poland

BLIRT develops, manufactures and commercializes standardized and customized solutions for proteins and enzymes as well as molecular biology reagents. Its offering includes proteins and enzymes that are critical to the life sciences industry and diagnostic kit manufacturers, especially for non-COVID-19 applications. BLIRT was founded in 1994 and is based in Gdansk, Poland.

Buy -
Mergr

Product

Company

Legal